Controlled Release Polymers in Implantable Systems

Abstract

Controlled release polymers form the material foundation of implantable drug delivery systems, determining how a therapeutic agent is released into tissue over hours, days, weeks, or months after implantation. The release profile that matters clinically -- the concentration-time curve at the target tissue site -- depends fundamentally on polymer choice: biodegradable versus non-biodegradable, hydrophilic versus hydrophobic, matrix versus reservoir architecture, and the specific chemistry of the polymer-drug interaction. Four decades of polymer chemistry development have produced a rich landscape of controlled release options, from the PLGA microsphere technology that underlies most approved long-acting injectable products to the stimuli-responsive systems that enable on-demand drug delivery. Matching the polymer platform to the clinical application remains, however, a non-trivial design decision where the trade-offs between release profile precision, mechanical integration, biocompatibility, and manufacturing feasibility require systematic evaluation. This study presents the Controlled Release Polymer Implantable System Assessment Framework (CRPISAF), evaluating five controlled release polymer classes -- biodegradable aliphatic polyesters (PLGA, PLA, PCL) in matrix and microsphere formats (BAE-MM), non-biodegradable silicone elastomer reservoir systems (NSE-RS), hydrogel-based swelling-controlled release platforms (HYD-SC), stimuli-responsive polymer systems with physiological triggering (SRP-PT), and self-assembling block copolymer nanocarriers for implant-delivered systemic therapy (SBC-NC)-- across four implantable system contexts: contraceptive and hormonal delivery implants, oncology local-delivery implants, chronic neurological condition implants, and ocular implants for posterior segment disease. Performance was scored using the Polymer System Effectiveness Score (PSES), a weighted composite of release profile fidelity (0.30), clinical performance (0.20), biocompatibility and degradation behaviour (0.20), manufacturing feasibility (0.15), and regulatory precedent (0.15). Biodegradable aliphatic polyesters achieved the highest PSES (0.897) through the best regulatory precedent (0.960) and strong clinical performance (0.900), reflecting five decades of accumulated evidence and approved products. Silicone elastomer reservoir systems ranked second (0.879) with the best release profile fidelity (0.920) through zero-order kinetics over multi-year periods. Hydrogels (0.863), stimuli-responsive systems (0.851), and self-assembling block copolymer nanocarriers (0.824) demonstrated specialised capabilities with context-specific advantages.